Abiopharma

🔍 Hippel James (Executive)

Company: BIO-TECHNE Corp (TECH)

Report Date: 2026-08-17

Detailed Transactions and Holdings:

• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-17 | Code: H | shares_owned_after: 170,183.00
• Acquired 22,438 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-17 | Code: A | equity_swap_involved: 0 | shares_owned_after: 22,438.00 | transaction_form_type: 4 | Footnotes: F5, F11, F11
• Acquired 36,459 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-17 | Code: A | equity_swap_involved: 0 | shares_owned_after: 36,459.00 | transaction_form_type: 4 | Footnotes: F5, F12, F12
• Holds 167,328 shares of Stock Options (Right to Buy) at $66.97 per share (Derivative)
  Date: 2026-08-17 | Code: H | Expires: 2027-08-05 | shares_owned_after: 167,328.00 | Footnotes: F1
• Holds 40,536 shares of Stock Options (Right to Buy) at $120.46 per share (Derivative)
  Date: 2026-08-17 | Code: H | Expires: 2028-08-06 | shares_owned_after: 40,536.00 | Footnotes: F1
• Holds 45,220 shares of Stock Options (Right to Buy) at $94.52 per share (Derivative)
  Date: 2026-08-17 | Code: H | Expires: 2029-08-15 | shares_owned_after: 45,220.00 | Footnotes: F1
• Holds 2,332 shares of Stock Options (Right to Buy) at $84.61 per share (Derivative)
  Date: 2026-08-17 | Code: H | Expires: 2030-08-15 | shares_owned_after: 2,332.00 | Footnotes: F1
• Holds 45,923 shares of Stock Options (Right to Buy) at $84.61 per share (Derivative)
  Date: 2026-08-17 | Code: H | Expires: 2030-08-15 | shares_owned_after: 45,923.00 | Footnotes: F2
• Holds 32,417 shares of Stock Options (Right to Buy) at $74.91 per share (Derivative)
  Date: 2026-08-17 | Code: H | Expires: 2034-08-15 | shares_owned_after: 32,417.00 | Footnotes: F3
• Holds 37,632 shares of Stock Options (Right to Buy) at $53.6 per share (Derivative)
  Date: 2026-08-17 | Code: H | Expires: 2035-08-15 | shares_owned_after: 37,632.00 | Footnotes: F4
• Holds 24,062 shares of Performance Restricted Stock Units (Derivative)
  Date: 2026-08-17 | Code: H | shares_owned_after: 24,062.00 | Footnotes: F5, F6, F6
• Holds 29,420 shares of Performance Restricted Stock Units (Derivative)
  Date: 2026-08-17 | Code: H | shares_owned_after: 29,420.00 | Footnotes: F5, F7, F7
• Holds 4,011 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-17 | Code: H | shares_owned_after: 4,011.00 | Footnotes: F5, F8, F8
• Holds 23,089 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-17 | Code: H | shares_owned_after: 23,089.00 | Footnotes: F5, F9, F9
• Holds 9,807 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-17 | Code: H | shares_owned_after: 9,807.00 | Footnotes: F5, F10, F10

Footnotes:

• F1: Fully exercisable.
• F2: Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026.
• F3: Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028.
• F4: Options to purchase 12,544 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
• F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
• F6: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
• F7: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
• F8: 4,011 restricted stock units vest on 8/15/2027.
• F9: 11,545 restricted stock units vest on 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027.
• F10: 4,903 restricted stock units vest on 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028.
• F11: 7,479 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 7,480 restricted stock units vest on 8/17/2029.
• F12: 36,459 restricted stock units vest on 8/17/2029.